Format

Send to

Choose Destination
Patient Prefer Adherence. 2017 Jun 27;11:1071-1081. doi: 10.2147/PPA.S135957. eCollection 2017.

Access to credible information on schizophrenia patients' medication adherence by prescribers can change their treatment strategies: evidence from an online survey of providers.

Author information

1
Precision Health Economics, Los Angeles, CA.
2
Health Analytics, Columbia, MD.
3
Otsuka Pharmaceutical Development & Commercialization, Inc.
4
ODH, Inc., Princeton, NJ.
5
Schaeffer Center for Health Policy and Economics, University of Southern California, Los Angeles, CA.
6
Department of Psychiatry, New York University School of Medicine, New York, NY, USA.

Abstract

OBJECTIVE:

Overestimating patients' medication adherence diminishes the ability of psychiatric care providers to prescribe the most effective treatment and to identify the root causes of treatment resistance in schizophrenia. This study was conducted to determine how credible patient drug adherence information (PDAI) might change prescribers' treatment decisions.

METHODS:

In an online survey containing 8 clinical case vignettes describing patients with schizophrenia, health care practitioners who prescribe antipsychotics to patients with schizophrenia were instructed to choose a preferred treatment recommendation from a set of predefined pharmacologic and non-pharmacologic options. The prescribers were randomly assigned to an experimental or a control group, with only the experimental group receiving PDAI. The primary outcome was the prescribers' treatment choice for each case. Between-group differences were analyzed using multinomial logistic regression.

RESULTS:

A convenience sample (n=219) of prescribers completed the survey. For 3 nonadherent patient vignettes, respondents in the experimental group were more likely to choose a long-acting injectable antipsychotic compared with those in the control group (77.7% experimental vs 25.8% control; P<0.001). For 2 adherent but poorly controlled patient vignettes, prescribers who received PDAI were more likely to increase the antipsychotic dose compared with the control group (49.1% vs 39.1%; P<0.001). For the adherent and well-controlled patient vignette, respondents in both groups made similar treatment recommendations across all choices (P=0.099), but respondents in the experimental arm were more likely to recommend monitoring clinical stability (87.2% experimental vs 75.5% control, reference group).

CONCLUSION:

The results illustrate how credible PDAI can facilitate more appropriate clinical decisions for patients with schizophrenia.

KEYWORDS:

adherence; case vignettes; long-acting injectables; schizophrenia; treatment decision

Conflict of interest statement

Disclosure Jason Shafrin, Suepattra G May, Anshu Shrestha, and Darius Lakdawalla are employees of Precision Health Economics, a health care consulting firm that received funding for this study from Otsuka. Charles Ruetsch and Nicole Gerlanc are employees of Health Analytics, LLC, a contract research company compensated by Otsuka to conduct the study. Felicia Forma is an employee of Otsuka Pharmaceutical Development & Commercialization, Inc. Ainslie Hatch is an employee of ODH, Inc and was an employee of Otsuka Pharmaceutical Development and Commercialization during this research project. Jean-Pierre Lindenmayer is a paid consultant for Otsuka and has received research support from Janssen, Alkermes, Forum, Neurocrine, and Avanir. The authors report no other conflicts of interest in this work.

Supplemental Content

Full text links

Icon for Dove Medical Press Icon for PubMed Central
Loading ...
Support Center